| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2024-02-06 | ACORN BIOVENTURES, L.P. | Cardiff Oncology, Inc. | 1,946,762 | 4.2% | EDGAR |
| SC 13G/A | 2023-02-14 | CAXTON CORP | Cardiff Oncology, Inc. | 983,607 | 2.2% | EDGAR |
| SC 13G/A | 2023-02-09 | JANUS HENDERSON GROUP PLC | Cardiff Oncology, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2023-01-26 | ACORN BIOVENTURES, L.P. | Cardiff Oncology, Inc. | 3,043,173 | 6.4% | EDGAR |
| SC 13G | 2023-01-26 | ACORN BIOVENTURES, L.P. | Cardiff Oncology, Inc. | 3,043,173 | 6.4% | EDGAR |
| SC 13G | 2022-07-08 | BlackRock Inc. | Cardiff Oncology, Inc. | 671,967 | 1.6% | EDGAR |
| SC 13G/A | 2022-02-14 | Avidity Partners Management LP | Cardiff Oncology, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2022-02-14 | CAXTON CORP | Cardiff Oncology, Inc. | 3,479,340 | 8.1% | EDGAR |
| SC 13G/A | 2022-02-14 | Corriente Advisors, LLC | Cardiff Oncology, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2022-02-10 | JANUS HENDERSON GROUP PLC | Cardiff Oncology, Inc. | 3,523,012 | 8.4% | EDGAR |
| SC 13G/A | 2022-02-09 | STATE STREET CORP | Cardiff Oncology, Inc. | - | 1.6% | EDGAR |
| SC 13G | 2022-02-04 | BlackRock Inc. | Cardiff Oncology, Inc. | 2,532,248 | 6.0% | EDGAR |
| SC 13G | 2021-11-19 | PFIZER INC | Cardiff Oncology, Inc. | 2,411,575 | 5.8% | EDGAR |
| SC 13G/A | 2021-02-16 | CAXTON CORP | Cardiff Oncology, Inc. | 3,098,447 | 8.8% | EDGAR |
| SC 13G | 2021-02-16 | Corriente Advisors, LLC | Cardiff Oncology, Inc. | 2,000,000 | 5.7% | EDGAR |
| SC 13G/A | 2021-02-12 | Opaleye Management Inc. | Cardiff Oncology, Inc. | 9 | 11.0% | EDGAR |
| SC 13G | 2021-02-12 | JANUS HENDERSON GROUP PLC | Cardiff Oncology, Inc. | 2,137,671 | 6.1% | EDGAR |
| SC 13G | 2021-02-11 | STATE STREET CORP | Cardiff Oncology, Inc. | - | 7.2% | EDGAR |
| SC 13G/A | 2021-02-10 | RA CAPITAL MANAGEMENT, L.P. | Cardiff Oncology, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2021-02-02 | Avidity Partners Management LP | Cardiff Oncology, Inc. | 2,153,600 | 6.1% | EDGAR |